Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| SoundHound AI | Pfizer | |
|---|---|---|
| Moat rating | narrow The FY2025 10-K describes a real but limited edge: after an automotive design win a competing product may not be able to displace the winner because it is 'very unlikely that a customer will change complex technology until a product model is revamped', and it claims technical barriers to entry and cites over 359 granted and over 102 pending patents. The same filing concedes intense, price-sensitive competition from larger rivals that may be able to offer competing functionality 'at lower cost or free of charge' within larger offerings, possible pricing pressure from OEMs, master service agreements customers can terminate on six months to one year of prior written notice, and, to date, substantial net losses and negative cash flows from operating activities. The stickiness is real, but it has not yet produced profits. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | switching costs The stickiest advantage in the 10-K is design-win lock-in: a product that did not win an OEM or Tier-1 design may not be able to displace the winner until the customer begins a new selection process, because the 10-K says customers are very unlikely to change complex technology until a product model is revamped. Private domains make SoundHound a long-term "partner" (the 10-K's quotation marks) because subscribing customers retain the ability to iterate and update their content on its platform. Patents are the weaker source: the filing warns that competitors 'may independently develop technologies that are substantially the same or superior' without infringing its rights. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | behind The 10-K calls SoundHound 'a global leader in conversational intelligence' with 'best-in-class speed and accuracy', but these are the company's own claims and it gives no share figure. Apart from the company's own positioning, such as its belief that some legacy vendors offer dated technologies, the 10-K's comparisons with rivals run against SoundHound: some current or potential competitors are large technology companies that have 'significantly greater financial, technical and marketing resources than SoundHound does', they may be able to respond more rapidly to new or emerging technologies, and its large competitors may have greater access to customer data, which the 10-K says provides them with a competitive advantage in developing new products and technologies. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak The 10-K flags price sensitivity among customers, rival alternatives offered 'at significantly lower costs or free of charge', and the strong purchasing power of major OEMs, under which SoundHound may be expected to quote fixed prices or be forced to accept annual price-reduction commitments. GAAP gross margin, computed from the 10-K's revenue and cost of revenue, fell from 75.4% (FY2023) to 48.9% (FY2024) and 42.4% (FY2025). The company attributes both declines primarily to acquisitions: the FY2024 10-K cites Amelia and SYNQ3, including SYNQ3's lower-margin call-center agent business and amortization of acquired intangibles, and the FY2025 10-K cites Amelia and Interactions, including $14.1M and $0.8M of amortization of acquired intangibles. Neither passage attributes the decline to pricing. The Q2 2026 release (8-K filed 2026-08-05) reports GAAP gross margin up 6.1 points year over year to 45.1%, with non-GAAP gross margin flat at 58.4%. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | SoundHound sells independent, white-label voice and agentic AI to carmakers, TV/IoT makers, restaurants and enterprises. Its 10-K pitches this as the alternative to big-tech assistants that take over a brand's users and data. Its defensibility rests mainly on automotive design wins, which the 10-K says customers are very unlikely to change until a product model is revamped. It layered on the Amelia (Aug 2024) and Interactions (Sep 2025) acquisitions, and it completed the LivePerson acquisition on 2026-09-04 per that day's 8-K, whose press release cites a strengthened IP portfolio of over 750 patents. Against that, the 10-K lists rivals with far greater resources and data that may be able to offer competing functionality at lower cost or free, customers that may develop competing products, competitors that may build their own solutions on open-source software, and possible OEM pricing pressure. The 10-K reports substantial net losses and negative operating cash flows to date, and GAAP gross margin fell from 75.4% (FY2023) to 42.4% (FY2025), a decline the company attributes mainly to acquisition mix and amortization. The advantage looks narrow and not yet proven economically. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Voice and agentic AI layer that OEMs, restaurants and enterprises embed under their own brand. Per the 10-K it combines its domains with third-party LLMs such as OpenAI's ChatGPT and runs on hosting facilities and third-party public clouds. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.15 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |